New study finds patients on strong antiplatelet meds face higher death risk after a brain bleed, while aspirin alone shows no increased risk. Research analyzed New study finds patients on strong antiplatelet meds face higher death risk after a brain bleed, while aspirin alone shows no increased risk. Research analyzed

Study Links Stronger Antiplatelet Medications to Higher Mortality After Brain Bleeds

2026/01/29 18:30
3 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

Analysis of hospital registry data spanning a decade indicates that individuals hospitalized for bleeding in the brain who were taking multiple antiplatelet medications or medications stronger than aspirin faced a higher likelihood of death before discharge compared to those not on any antiplatelet therapy. The preliminary study, to be presented at the American Stroke Association’s International Stroke Conference 2026, examined data from over 400,000 adults in the U.S. hospitalized for intracranial hemorrhage without traumatic brain injury or other stroke types.

Antiplatelet medications, which prevent blood clot formation by making platelets less sticky, are commonly prescribed to treat and prevent heart attacks and ischemic strokes. While aspirin is a mild anti-clotting medication often used for stroke prevention, stronger alternatives like clopidogrel, prasugrel, and ticagrelor are sometimes prescribed alongside aspirin after cardiovascular events. Lead study author Santosh Murthy, M.D., M.P.H., noted that previous research grouped all antiplatelet therapies together when assessing outcomes after brain bleeds, prompting this investigation into how different medications or combinations affect mortality and recovery.

The research utilized data from the American Heart Association’s Get With The Guidelines-Stroke Registry, excluding patients on anticoagulant medication. Among 426,481 people hospitalized with intracranial hemorrhage, 109,512 were taking only one antiplatelet, 17,009 were on two antiplatelet medications, and 300,558 had no antiplatelet treatment before the bleed. Outcomes were categorized as unfavorable if a patient died or was sent to hospice care versus favorable if discharged home or to another care setting.

Findings revealed that patients taking aspirin alone did not have an increased risk of dying in the hospital and actually had lower odds of an unfavorable outcome. In contrast, those on stronger antiplatelet medications, either alone or combined with aspirin, showed an increased risk of in-hospital death. There was also a trend toward higher unfavorable outcomes in these groups. American Stroke Association volunteer expert Jonathan Rosand, M.D., M.Sc., FAHA, emphasized that while dual antiplatelet therapy and newer generation drugs have improved lives for those with coronary artery disease, they carry risks, including a slightly higher chance of bleeding strokes that may be more fatal.

Murthy clarified that the results do not suggest people should avoid antiplatelet medications if recommended, but rather highlight how pre-bleed medication types may influence outcomes. The study did not analyze the risk of having a brain bleed from different antiplatelet medications. Current guidelines do not recommend platelet transfusions for brain bleed patients on antiplatelet medications unless immediate surgery is needed, but future research could explore whether transfusions affect outcomes differently based on therapy type. The study’s limitations include not accounting for specific brain bleed characteristics like blood amount or location, which could influence severity and outcomes.

Intracranial hemorrhage accounts for about 10% of all strokes in the U.S., according to the American Heart Association’s 2026 Heart Disease and Stroke Statistics. The findings open the door to research on improving care for hospitalized brain bleed patients on antiplatelet medications, potentially informing management strategies beyond current practices of discontinuing medications post-bleed. As stroke remains a leading cause of death, this study underscores the need for tailored treatment approaches in high-risk scenarios.

Blockchain Registration, Verification & Enhancement provided by NewsRamp™

This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Study Links Stronger Antiplatelet Medications to Higher Mortality After Brain Bleeds.

The post Study Links Stronger Antiplatelet Medications to Higher Mortality After Brain Bleeds appeared first on citybuzz.

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Alpha Ladder Group and MetaComp Partner with Maqam International Holding, an Abu Dhabi (UAE) company, to Advance RWA Tokenisation and Web2.5 Payments Across Singapore-UAE Corridor

Alpha Ladder Group and MetaComp Partner with Maqam International Holding, an Abu Dhabi (UAE) company, to Advance RWA Tokenisation and Web2.5 Payments Across Singapore-UAE Corridor

Alpha Ladder Group (“Alpha Ladder”), a Singapore-headquartered Digital Green Group driving sustainable financial and technology innovation through subsidiaries
Share
Globalfintechseries2026/04/02 19:17
68% of global BTC miners came from the U.S., Russia, and China, Q1 2026

68% of global BTC miners came from the U.S., Russia, and China, Q1 2026

The post 68% of global BTC miners came from the U.S., Russia, and China, Q1 2026 appeared on BitcoinEthereumNews.com. Bitcoin (BTC) hashrate remained largely dominated
Share
BitcoinEthereumNews2026/04/02 18:16
Franklin Templeton CEO Dismisses 50bps Rate Cut Ahead FOMC

Franklin Templeton CEO Dismisses 50bps Rate Cut Ahead FOMC

The post Franklin Templeton CEO Dismisses 50bps Rate Cut Ahead FOMC appeared on BitcoinEthereumNews.com. Franklin Templeton CEO Jenny Johnson has weighed in on whether the Federal Reserve should make a 25 basis points (bps) Fed rate cut or 50 bps cut. This comes ahead of the Fed decision today at today’s FOMC meeting, with the market pricing in a 25 bps cut. Bitcoin and the broader crypto market are currently trading flat ahead of the rate cut decision. Franklin Templeton CEO Weighs In On Potential FOMC Decision In a CNBC interview, Jenny Johnson said that she expects the Fed to make a 25 bps cut today instead of a 50 bps cut. She acknowledged the jobs data, which suggested that the labor market is weakening. However, she noted that this data is backward-looking, indicating that it doesn’t show the current state of the economy. She alluded to the wage growth, which she remarked is an indication of a robust labor market. She added that retail sales are up and that consumers are still spending, despite inflation being sticky at 3%, which makes a case for why the FOMC should opt against a 50-basis-point Fed rate cut. In line with this, the Franklin Templeton CEO said that she would go with a 25 bps rate cut if she were Jerome Powell. She remarked that the Fed still has the October and December FOMC meetings to make further cuts if the incoming data warrants it. Johnson also asserted that the data show a robust economy. However, she noted that there can’t be an argument for no Fed rate cut since Powell already signaled at Jackson Hole that they were likely to lower interest rates at this meeting due to concerns over a weakening labor market. Notably, her comment comes as experts argue for both sides on why the Fed should make a 25 bps cut or…
Share
BitcoinEthereumNews2025/09/18 00:36

$30,000 in PRL + 15,000 USDT

$30,000 in PRL + 15,000 USDT$30,000 in PRL + 15,000 USDT

Deposit & trade PRL to boost your rewards!